Deals

Sept. 17 Company Quick Takes: Priority Review for Merck Ebola vaccine; plus Edgewise’s debut, Adaptive, AskBio and Acceleron

Merck Ebola vaccine granted Priority Review  FDA accepted and granted Priority Review to a BLA from Merck & Co. Inc. (NYSE:MRK) for its Ebola vaccine V920 (rVSV-ZEBOV). The candidate has a PDUFA date of March...

Bayer invests $20M in One Drop's digital platform

As digital health's footprint continues to grow, Bayer is leading One Drop's $40 million series B round and licensing its diabetes self-management platform for use in other disease areas. Bayer AG (Xetra:BAYN) said Tuesday it...

Amgen taps Hummingbird’s tech for epitope-based antibody selection

Hummingbird’s method of identifying an antigen’s binding epitopes and screening antibodies has garnered the Singaporean company a new partner in Amgen. The companies revealed Monday that they will discover antibodies against undisclosed targets using Hummingbird’s...

Lundbeck enters migraine race with $2B takeout of Alder

Lundbeck will add a CGRP inhibitor to its neurology pipeline by buying Alder for just shy of $2 billion, but the Scandinavian pharma will be playing catch-up as eptinezumab will likely be fourth among drugs...

After single exit, Avalon seeks path forward for build-to-buy assets from GSK deal

With GSK effectively bowing out of a 2013 build-to-buy deal with Avalon Ventures after delivering just one exit, the VC is seeking to navigate a future for a handful of Phase I-ready programs it created...

Sept. 11 Company Quick Takes: Glaxo to buy Sitari; plus Aimmune, Xeris, Puma and United Therapeutics

GSK acquires celiac company Sitari  GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) is acquiring Sitari Pharmaceuticals Inc. (La Jolla, Calif.), the first company formed and funded under a 2013 build-to-buy partnership between Avalon Ventures and the pharma. Financial...

Anokion raises $40M series B, grabs back programs from spinout

Alongside raising $40 million in a series B round, autoimmune company Anokion said Wednesday it will acquire Kanyos Bio, a company it spun out and partnered with Astellas in 2015. Versant Ventures, Novartis Venture Fund,...

Taiwan’s JHL to terminate biosimilars programs in Genentech trade secret settlement

JHL Biotech and Genentech have settled a civil suit involving allegations that the Taiwanese start-up stole the Roche unit’s trade secrets. Under terms of the settlement, JHL Biotech Inc. (Zhubei, Taiwan) has agreed to “abandon...

Sept. 5 Company Quick Takes: Zafgen exploring alternatives; plus BridgeBio, Global Blood, Akouos, Mallinckrodt, uBiome

Zafgen evaluating strategic options  Metabolic company Zafgen Inc. (NASDAQ:ZFGN) has retained advisory firm MTS Health Partners to explore strategic alternatives after receiving new preclinical data that the company believes will be insufficient for FDA to...

In third pharma deal, IFM partners cGAS-STING unit with Novartis

IFM Therapeutics' subsidiary model continues to pay off as the innate immune company scores its third high-value pharma deal in as many years. The biotech teamed up with Novartis Thursday in a collaboration and acquisition...

Via $950M Semma takeout, Vertex moves into diabetes and cell therapy

As Vertex continues to add new therapeutic areas and modalities to its portfolio, the company will pay $950 million in cash to acquire Semma and its stem cell-derived islet program. The acquisition marks Vertex's entry...

With Rova-T killed, spotlight shifts to AbbVie’s hematology, immunology franchises

The final clinical failure of a program AbbVie once regarded as the "anchor asset" in its solid tumor portfolio leaves AbbVie with little or nothing to show for its acquisition of Stemcentrx in 2016 for...

Immatics reels in $75M from Celgene in first cell therapy deal

Immatics netted its largest upfront cash haul yet in an option deal with Celgene to develop TCR-based cell therapies to treat solid tumors. The $75 million upfront payment is the largest one-time cash infusion for...

Aug. 27 Company Quick Takes: GSK licenses Ionis HBV program; plus Adaptimmune-Noile, Purdue, Presage-BMS, Kyowa, Alexion, Viela, Kintai, OncoNano

GSK opts into Ionis' HBV program  Positive Phase II data prompted GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to exercise its option to license exclusive, worldwide rights to an antisense chronic HBV program from Ionis Pharmaceuticals Inc. (NASDAQ:IONS)....

Modis deal bolsters Zogenix’s late-stage, rare disease pipeline

With its acquisition of Modis, Zogenix will need to blaze a regulatory trail for Modis’ thymidine kinase 2 deficiency program while still pushing its own Dravet syndrome therapy through regulatory approval. Zogenix Inc. (NASDAQ:ZGNX) said...